Lantheus Holdings Inc
LNTH54.900USD
-0.600-1.08%
Fechamento 08/29, 16:00（ET）Cotações atrasadas em 15 min
3.73BValor de mercado
14.68P/L TTM
Mais detalhes de Lantheus Holdings Inc Empresa
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. It classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, and others. Its pipeline includes B amyloid positron emission tomography (PET) imaging agent, NAV-4694, also known as F18-flutafuranol. It has pre-clinical assets, specifically the TROP2 and DUNP19.
Informações da empresa
Código da empresaLNTH
Nome da EmpresaLantheus Holdings Inc
Data de listagemJun 25, 2015
CEOMr. Brian A. Markison
Número de funcionários808
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 25
Endereço331 Treble Cove Road
CidadeNORTH BILLERICA
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal01862
Telefone19786718001
Sitehttps://www.lantheus.com/
Código da empresaLNTH
Data de listagemJun 25, 2015
CEOMr. Brian A. Markison
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Mary Anne Heino
Ms. Mary Anne Heino
Chairman of the Board
Chairman of the Board
584.72K
-4.27%
Mr. Brian A. Markison
Mr. Brian A. Markison
Chief Executive Officer, Director
Chief Executive Officer, Director
232.42K
+35.31%
Dr. Jean-Claude Provost, M.D.
Dr. Jean-Claude Provost, M.D.
Chief Scientific Officer
Chief Scientific Officer
38.84K
-31.55%
Dr. James H. (Jim) Thrall
Dr. James H. (Jim) Thrall
Independent Director
Independent Director
35.74K
+7.64%
Ms. Julie H. Mchugh
Ms. Julie H. Mchugh
Lead Independent Director
Lead Independent Director
25.96K
-16.67%
Dr. Gerard Ber, Ph.D.
Dr. Gerard Ber, Ph.D.
Independent Director
Independent Director
23.36K
+10.09%
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
9.90K
+34.47%
Dr. Phuong Khanh (P. K.) Morrow, M.D.
Dr. Phuong Khanh (P. K.) Morrow, M.D.
Independent Director
Independent Director
3.10K
+450.62%
Mr. Samuel R. (Sam) Leno
Mr. Samuel R. (Sam) Leno
Independent Director
Independent Director
--
--
Ms. Jamie Spaeth
Ms. Jamie Spaeth
Chief People Officer
Chief People Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Mary Anne Heino
Ms. Mary Anne Heino
Chairman of the Board
Chairman of the Board
584.72K
-4.27%
Mr. Brian A. Markison
Mr. Brian A. Markison
Chief Executive Officer, Director
Chief Executive Officer, Director
232.42K
+35.31%
Dr. Jean-Claude Provost, M.D.
Dr. Jean-Claude Provost, M.D.
Chief Scientific Officer
Chief Scientific Officer
38.84K
-31.55%
Dr. James H. (Jim) Thrall
Dr. James H. (Jim) Thrall
Independent Director
Independent Director
35.74K
+7.64%
Ms. Julie H. Mchugh
Ms. Julie H. Mchugh
Lead Independent Director
Lead Independent Director
25.96K
-16.67%
Dr. Gerard Ber, Ph.D.
Dr. Gerard Ber, Ph.D.
Independent Director
Independent Director
23.36K
+10.09%
Detalhamento da receita
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
PYLARIFY
257.65M
0.00%
DEFINITY
79.21M
0.00%
TechneLite
19.71M
0.00%
Strategic partnerships and other
10.75M
0.00%
Other precision diagnostics
5.44M
0.00%
Radiopharmaceutical oncology
0.00
0.00%
Sem dados
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
PYLARIFY
257.65M
0.00%
DEFINITY
79.21M
0.00%
TechneLite
19.71M
0.00%
Strategic partnerships and other
10.75M
0.00%
Other precision diagnostics
5.44M
0.00%
Radiopharmaceutical oncology
0.00
0.00%
Distribuição de ações
Atualizado em: sex, 15 de ago
Atualizado em: sex, 15 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
11.03%
Janus Henderson Investors
10.21%
The Vanguard Group, Inc.
10.03%
Fidelity Management & Research Company LLC
6.08%
Farallon Capital Management, L.L.C.
4.88%
Outro
57.78%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
11.03%
Janus Henderson Investors
10.21%
The Vanguard Group, Inc.
10.03%
Fidelity Management & Research Company LLC
6.08%
Farallon Capital Management, L.L.C.
4.88%
Outro
57.78%
Tipos de investidores
Investidores
Proporção
Investment Advisor
57.48%
Investment Advisor/Hedge Fund
45.03%
Hedge Fund
6.89%
Research Firm
3.61%
Individual Investor
2.32%
Pension Fund
1.94%
Bank and Trust
1.50%
Sovereign Wealth Fund
0.74%
Venture Capital
0.11%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
1039
82.20M
120.88%
-4.84M
2025Q1
1066
83.20M
120.27%
-2.89M
2024Q4
1033
78.65M
114.86%
-4.64M
2024Q3
1003
73.69M
106.06%
-7.92M
2024Q2
959
71.82M
103.63%
-10.29M
2024Q1
912
71.21M
103.87%
-11.25M
2023Q4
868
73.50M
107.32%
-9.24M
2023Q3
828
74.80M
109.31%
-3.81M
2023Q2
790
72.85M
106.61%
-3.94M
2023Q1
733
71.94M
105.47%
-6.73M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
7.79M
11.27%
+17.69K
+0.23%
Mar 31, 2025
Janus Henderson Investors
6.26M
9.05%
-252.58K
-3.88%
May 30, 2025
The Vanguard Group, Inc.
6.99M
10.1%
-242.63K
-3.36%
Mar 31, 2025
Fidelity Management & Research Company LLC
2.17M
3.14%
+148.84K
+7.36%
Mar 31, 2025
Farallon Capital Management, L.L.C.
6.02M
8.71%
+707.00K
+13.30%
Mar 31, 2025
State Street Global Advisors (US)
2.64M
3.81%
-4.26K
-0.16%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.78M
2.57%
+94.57K
+5.62%
Mar 31, 2025
Wellington Management Company, LLP
909.10K
1.31%
+685.29K
+306.19%
Mar 31, 2025
Westfield Capital Management Company, L.P.
1.59M
2.3%
+34.05K
+2.19%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
1.41M
2.04%
-96.91K
-6.42%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: qua, 6 de ago
Atualizado em: qua, 6 de ago
Nome
Proporção
Invesco S&P MidCap 400 GARP ETF
2.15%
Harbor Health Care ETF
2.04%
Alpha Architect US Quantitative Value ETF
1.96%
SPDR S&P Health Care Equipment ETF
1.85%
Distillate Small/Mid Cash Flow ETF
1.13%
Invesco S&P MidCap 400 Pure Growth ETF
1.12%
Janus Henderson US Sustainable Equity ETF
1.12%
Fidelity Stocks for Inflation ETF
1.09%
Pacer US Cash Cows Growth ETF
0.75%
First Trust Small Cap US Equity Select ETF
0.68%
Ver Mais
Invesco S&P MidCap 400 GARP ETF
Proporção2.15%
Harbor Health Care ETF
Proporção2.04%
Alpha Architect US Quantitative Value ETF
Proporção1.96%
SPDR S&P Health Care Equipment ETF
Proporção1.85%
Distillate Small/Mid Cash Flow ETF
Proporção1.13%
Invesco S&P MidCap 400 Pure Growth ETF
Proporção1.12%
Janus Henderson US Sustainable Equity ETF
Proporção1.12%
Fidelity Stocks for Inflation ETF
Proporção1.09%
Pacer US Cash Cows Growth ETF
Proporção0.75%
First Trust Small Cap US Equity Select ETF
Proporção0.68%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
